Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials
PR96146
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BEIJING dldate May 24, 2022 /PRNewswire=KYODO JBN/ --
Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals
(Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two
posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and
virtually from June 3-7, 2022. The posters describe updates from two phase I
clinical studies in Australia for internally developed monoclonal antibodies
(mAbs) YH003 (anti-CD40, abstract # 2603) and YH001 (anti-CTLA-4, abstract #
2602). Both YH003 and YH001 demonstrate favorable safety and tolerability
profiles and preliminary efficacy when administered in combination with
anti-PD-1 mAb to patients with advanced solid tumors.
The details of the presentations are as follows:
Title
A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal
antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with
advanced solid tumors.
(https://meetings.asco.org/abstracts-presentations/210362)
Corresponding author
Dr. Jermaine Coward
Trial
NCT04481009
Abstract number
2603
Session
Poster Session 3: Developmental Therapeutics—Immunotherapy
Title
A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal
antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients
with advanced solid tumors.
(https://meetings.asco.org/abstracts-presentations/210326)
Corresponding author
Dr. Vinod Ganju
Trial
NCT04357756
Abstract number
2602
Session
Poster Session 3: Developmental Therapeutics—Immunotherapy
Both posters will be presented in-person on Sunday, June 5 from 8:00 AM–11:00
AM CT.
About YH003
YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single
agent or in combination with anti-PD-1 mAb drugs, YH003 demonstrated strong
anti-tumor effects against multiple tumor models in Biocytogen's humanized CD40
mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic
studies in mice indicate that YH003 significantly increased the infiltration of
anti-tumor T cells into tumors. Currently, YH003 is undergoing phase II
multi-regional clinical trials (MRCTs) for the treatment of patients with
unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).
About YH001
YH001 is an anti-CTLA-4 monoclonal antibody. CTLA-4 is a key target for tumor
immunotherapies, due to the potential to enhance the immune response to tumor
cells and promote removal of regulatory T cells from the tumor
microenvironment. Blocking the inhibitory signals from both CTLA-4 and PD-1 to
enhance the anti-tumor responses is considered a promising tumor immunotherapy,
as they control different types of T cells. Currently, YH001 is undergoing
phase II MRCTs for the treatment of patients with advanced non-small cell lung
cancer (NSCLC) and hepatocellular carcinoma (HCC). Moreover, Biocytogen/Eucure
Biopharma has entered into a collaborative partnership agreement with TRACON
Pharmaceuticals (NASDAQ: TCON) for the development of YH001 for multiple
oncology indications, including soft tissue sarcoma, in North America.
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the
mission of clinical development for Biocytogen's R&D pipelines. Relying on a
strong clinical development team and extensive clinical development experience,
Eucure Biopharma focuses on antibody drug therapy for oncology and other
indications. The company has established a product pipeline for more than 10
targets, with two products in phase II MRCT and two in phase I. For more
information, please visit www.eucure.com (http://www.eucure.com/).
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology
company that drives the research and development of novel antibody-based drugs
with innovative technologies. Using its proprietary RenMabTM /RenLite® mouse
platforms for fully human monoclonal and bispecific antibody development,
Biocytogen has integrated its in vivo drug efficacy screening platforms and
strong clinical development expertise to streamline the entire drug development
process. Biocytogen is undertaking a large-scale project to develop antibody
drugs for more than 1000 targets, known as Project Integrum, and has entered
ongoing collaborations with dozens of partners worldwide to produce a variety
of first-in-class and/or best-in-class antibody drugs. The company's pipeline
includes 12 core products, among which two products are in phase II MRCTs and
two products are in phase I. Headquartered in Beijing, Biocytogen has branches
in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more
information, please visit www.biocytogen.com (http://www.biocytogen.com/).
SOURCE: Biocytogen
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=421880
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。